National University Corp. Tokyo Medical & Dental University is a private company headquartered in Japan that operates as an national educational institution for dentistry.

Beijing Xinnuo Weikang Technology Co., Ltd., established on 2017-11-30, Business scope includes technology development,Serve,to promote,transfer,consult;hospital management(Does not include medical activities);health management,Health Advisory(Except for medical treatment activities subject to approval);Medical Research and Experimental Development;Sales of medical devices Class I,Class II,Chemical Products(Does not contain dangerous chemicals and a class of precursor chemicals);Trademark agency;copyright agent;Conference Services;translation service;market survey;Organize cultural and artistic exchange activities(without show);Undertake the exhibition;Agent import and export;Import and export;Technology Import and Export;Professional contractors;Labor service;patent agency.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Patent agency and projects subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Accurate International is engaged in the research and development of regenerative medicines based on the four centers of organoid tissue and disease models. clinical medicine transformation, big data sharing, and smart device development.

Nuvelo, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. The Company’s development pipeline includes alfimeprase, a direct-acting fibrinolytic in Phase II development for the treatment of thrombotic-related disorders, including acute ischemic stroke and catheter occlusion (CO); NU172, a direct thrombin inhibitor in Phase I development for use as a short-acting anticoagulant during medical or surgical procedures, and preclinical candidate NU206 for the treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo has research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities. (Source: 10-K)

Kirin Pharma Co. Ltd. manufactures and sells pharmaceutical products. Its products include Nesp, Regpara Tablets, Espo, Phosblock and Gran. The company was founded in 2007 and is headquartered in Tokyo, Japan

OncoMed Pharmaceuticals, Inc. is a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and is listed on NASDAQ under the stock symbol OMED.

Tempus Labs, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL.

Ichimaru Pharcos Co. Ltd. is a Japanese private company. The firm specializes in research and development, manufacturing and selling of raw materials for cosmetics, health foods and quasi drugs.